GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (LTS:0JXZ) » Definitions » Common Stock

Galapagos NV (LTS:0JXZ) Common Stock : €293.9 Mil (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Galapagos NV Common Stock?

Galapagos NV's quarterly common stock stayed the same from Jun. 2024 (€293.9 Mil) to Sep. 2024 (€293.9 Mil) and stayed the same from Sep. 2024 (€293.9 Mil) to Dec. 2024 (€293.9 Mil).

Galapagos NV's annual common stock increased from Dec. 2022 (€293.6 Mil) to Dec. 2023 (€293.9 Mil) but then stayed the same from Dec. 2023 (€293.9 Mil) to Dec. 2024 (€293.9 Mil).


Galapagos NV Common Stock Historical Data

The historical data trend for Galapagos NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Common Stock Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 291.31 292.08 293.60 293.94 293.94

Galapagos NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.94 293.94 293.94 293.94 293.94

Galapagos NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Galapagos NV Headlines

No Headlines